Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
14 févr. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth...
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
13 févr. 2024 16h05 HE
|
Codexis, Inc.
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and...
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
01 févr. 2024 16h05 HE
|
Codexis, Inc.
BEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme...
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
27 déc. 2023 08h30 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé...
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
13 déc. 2023 16h06 HE
|
Codexis, Inc.; Aldevron
REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with...
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
13 déc. 2023 16h05 HE
|
Codexis, Inc.
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. ...
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
11 déc. 2023 07h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8,...
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
28 nov. 2023 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event...
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
14 nov. 2023 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler...
Codexis Reports Third Quarter 2023 Financial Results
02 nov. 2023 16h05 HE
|
Codexis, Inc.
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year Strong Financial Position Enables Projected Runway to...